Kalbe Farma provided earnings guidance for the year 2014 and 2015. The company expects to post weaker-than-expected full-year 2014 sales growth of 8-9% to IDR 17.4 trillion (USD 1.39 billion), due to weaker sales of non-Kalbe products distributed by the company. This compares with sales of IDR 16 trillion in the fiscal 2013, and Kalbe's previous 2014 full-year sales growth target of 11-13% to IDR 18.08 trillion.

However, sales in prescription drugs and health and nutrition products remained healthy, with the company expecting sales growth of 10%-15% in 2015. Net profit for 2014 is expected to be flat. The company has also set aside IDR 1 trillion -1.5 trillion for capital expenditure in 2015, most of which will go towards stepping up production capacities of pharmaceutical and nutrition products by 30-50%.

Kalbe has also allotted IDR 150-225 billion to create 10-15 new products.